Cas:179603-47-5 macrocarpal J manufacturer & supplier

Chemical Name:macrocarpal J

CAS.NO:179603-47-5

Synonyms:1,3-Benzenedicarboxaldehyde, 5-[(1S)-1-[(1S,4R,4aR,6R,8aS)-decahydro-4-hydroxy-6-(1-hydroxy-1-methylethyl)-4,8a-dimethyl-1-naphthalenyl]-3-methylbutyl]-2,4,6-trihydroxy-;2,4,6-Trihydroxy-5-{(1S)-1-[(1S,4R,4aR,6R,8aS)-4-hydroxy-6-(2-hydroxy-2-propanyl)-4,8a-dimethyldecahydro-1-naphthalenyl]-3-methylbutyl}isophthalaldehyde;Macrocarpal J

Molecular Formula:C₂₈H₄₂O₇

Molecular Weight:490.629

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:569.5±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.600

PSA:135.29000

Exact Mass:490.293060

LogP:7.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,3-Benzenedicarboxaldehyde, 5-[(1S)-1-[(1S,4R,4aR,6R,8aS)-decahydro-4-hydroxy-6-(1-hydroxy-1-methylethyl)-4,8a-dimethyl-1-naphthalenyl]-3-methylbutyl]-2,4,6-trihydroxy- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Macrocarpal J physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4,6-Trihydroxy-5-{(1S)-1-[(1S,4R,4aR,6R,8aS)-4-hydroxy-6-(2-hydroxy-2-propanyl)-4,8a-dimethyldecahydro-1-naphthalenyl]-3-methylbutyl}isophthalaldehyde Use and application,2,4,6-Trihydroxy-5-{(1S)-1-[(1S,4R,4aR,6R,8aS)-4-hydroxy-6-(2-hydroxy-2-propanyl)-4,8a-dimethyldecahydro-1-naphthalenyl]-3-methylbutyl}isophthalaldehyde technical grade,usp/ep/jp grade.

Related News: Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. Acetic acid 1-methyl-3-((1R,2S,3R,6S)-1,2,3-trimethyl-7-oxa-bicyclo[4.1.0]hept-2-yl)-propyl ester manufacturers Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. 5-bromo-3-(1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-1,3-dihydro-indol-2-one suppliers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. N-Cyclohexylmethyl-4-chlorbenzamid vendor & factory Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. ,Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion.